Literature DB >> 2567980

Designed diagnostic restriction fragment length polymorphisms for the detection of point mutations in ras oncogenes.

R Kumar1, L L Dunn.   

Abstract

The polymerase chain reaction (PCR) technique has greatly facilitated the identification of ras oncogenes by allele-specific hybridization of the PCR-amplified DNA to radioactively labelled oligonucleotide probes. In this study, we describe a different method which employs designed mismatch primers that create diagnostic restriction fragment length polymorphisms (RFLPs). This procedure allows the identification of point mutations in the amplified DNA without the use of any radioactive probes. We apply this method to the detection of specific point mutations in the rat H- and K-ras oncogenes in carcinogen-induced tumors. We also suggest strategies for the diagnostic RFLP analysis of most point mutations in the 12th and 61st codons of human ras oncogenes. This simple method is especially suitable for analyzing minuscule amounts of tissue samples where only a fraction of cells may carry activated oncogenes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2567980

Source DB:  PubMed          Journal:  Oncogene Res        ISSN: 0890-6467


  20 in total

1.  Fast screening methods to detect mutations of spectrin in subjects with hereditary elliptocytosis.

Authors:  L Boulanger; M C LeCompte; D Dhermy; M Garbarz
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

2.  High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.

Authors:  A Zimran; T Gelbart; B Westwood; G A Grabowski; E Beutler
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

3.  Detection of minority point mutations by modified PCR technique: a new approach for a sensitive diagnosis of tumor-progression markers.

Authors:  A Haliassos; J C Chomel; S Grandjouan; J Kruh; J C Kaplan; A Kitzis
Journal:  Nucleic Acids Res       Date:  1989-10-25       Impact factor: 16.971

4.  Molecular characterization of genetic mutations in human lactate dehydrogenase (LDH) B (H) variant.

Authors:  K Sudo; M Maekawa; A Tomonaga; T Tsukada; T Nakayama; M Kitamura; S S Li; T Kanno; J Toriumi
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

5.  A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity.

Authors:  H Funke; A von Eckardstein; P H Pritchard; J J Albers; J J Kastelein; C Droste; G Assmann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

6.  Specific patterns of oncogene activation in transplacentally induced tumors.

Authors:  S Sukumar; M Barbacid
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

7.  Molecular analysis of ras oncogenes in CIN III and in stage I and II invasive squamous cell carcinoma of the uterine cervix.

Authors:  J J O'Leary; R J Landers; I Silva; V Uhlmann; M Crowley; I Healy; K Luttich
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

8.  Population screening of lactate dehydrogenase deficiencies in Fukuoka Prefecture in Japan and molecular characterization of three independent mutations in the lactate dehydrogenase-B(H) gene.

Authors:  M Maekawa; K Sudo; K Nagura; S S Li; T Kanno
Journal:  Hum Genet       Date:  1994-01       Impact factor: 4.132

9.  Detection and characterization of new genetic mutations in individuals heterozygous for lactate dehydrogenase-B(H) deficiency using DNA conformation polymorphism analysis and silver staining.

Authors:  M Maekawa; K Sudo; M Kitajima; Y Matsuura; S S Li; T Kanno
Journal:  Hum Genet       Date:  1993-03       Impact factor: 4.132

10.  Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease.

Authors:  H Funke; A von Eckardstein; P H Pritchard; A E Hornby; H Wiebusch; C Motti; M R Hayden; C Dachet; B Jacotot; U Gerdes
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.